Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

The handoff is complete
February 2020
SHARING OPTIONS:

LONDON—GlaxoSmithKline plc (GSK) recently completed the divestment of its travel vaccines Rabipur, for the prevention of rabies, and Encepur, for the prevention of tick-borne encephalitis, to Bavarian Nordic. In keeping with the terms of the divestment agreement, Bavarian Nordic has paid GSK £308 million ($263 million) in an upfront payment, which will be followed by other milestone payments for a total consideration of up to £955 million.
 
“With the acquisition now completed, we can truly begin the commercial transformation of Bavarian Nordic, driven by established and proven commercial products, which along with our smallpox and monkeypox vaccine create a leading infectious disease franchise that will drive sustained profits and growth in the years ahead,” said Paul Chaplin, president and CEO of Bavarian Nordic.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.